|1.||Hancock, Kathy: 5 articles (04/2011 - 01/2004)|
|2.||Tsang, Victor C W: 5 articles (04/2011 - 01/2004)|
|3.||Pattabhi, Sowmya: 4 articles (04/2011 - 01/2004)|
|4.||Scheel, Christina M: 2 articles (04/2011 - 03/2005)|
|5.||Gilman, Robert H: 2 articles (04/2011 - 01/2010)|
|6.||Kovalenko, Victor A: 2 articles (04/2011 - 01/2010)|
|7.||Garcia, Hector H: 2 articles (04/2011 - 01/2010)|
|8.||Handali, Sukwan: 2 articles (04/2011 - 01/2010)|
|9.||Gonzalez, Armando E: 2 articles (04/2011 - 01/2010)|
|10.||Lee, Yeuk-Mui: 2 articles (04/2011 - 01/2010)|
12/01/1993 - "All but one animal developed latent PRV infection following challenge exposure; however, significant protection against PRV-induced signs was afforded by vaccination with either the NYVAC/PRV gp50 or NYVAC/PRV gII recombinant viruses, as well as with the inactivated PRV vaccine. "
03/01/1993 - "In conclusion, vaccination with a PrV mutant lacking glycoprotein gp50, which is unable to spread between animals because of a lack of formation of free infectious virions, can confer on pigs protection against challenge infection. "
09/01/1993 - "HSV-1 lacking gH and PRV lacking gp50 also were less competent in blocking infection of challenge virus. "
12/01/1987 - "In addition, gp50 synthesized in CHO cells protected pigs from lethal infection with PRV. "
12/01/1987 - "gp50 protected mice from PRV-induced mortality either when delivered via infection with a recombinant vaccinia virus or when administered as a subunit vaccine produced in a eucaryotic cell line, Chinese hamster ovary (CHO) cells. "
03/01/1994 - "Our results show that a gp50 null mutant has a greatly reduced virulence for pigs, and that pigs immunized with such a mutant were protected from clinical signs of Aujeszky's disease after a challenge inoculation with the virulent wild-type PRV strain NIA-3. "
12/01/1987 - "Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells."
03/01/1994 - "To establish whether phenotypically-complemented PRV gp50 null mutants and gp50 + gp63 double mutants could be used as live vaccines against Aujeszky's disease, the virulence and immunogenicity of these mutants were tested in pigs. "
01/01/1994 - "Evaluation of a recombinant vaccinia virus containing pseudorabies (PR) virus glycoprotein genes gp50, gII, and gIII as a PR vaccine for pigs."
01/01/1994 - "Evaluation of swinepox virus as a vaccine vector in pigs using an Aujeszky's disease (pseudorabies) virus gene insert coding for glycoproteins gp50 and gp63."
01/01/2004 - "A preliminary evaluation of recombinant GP50 in a Western blot assay showed 100% specificity for cysticercosis and 90% sensitivity for cysticercosis positive serum samples reactive with the GP50 component of LLGP."
01/01/2004 - "GP50, a Taenia solium protein diagnostic for cysticercosis has been cloned, sequenced, and characterized. "
01/31/2008 - "Upon evaluation of the specificity of recombinant GP50 (rGP50) in a western blot assay, we observed that 12.5% (21/168) of the serum samples from persons with a variety of parasitic infections other than cysticercosis reacted positive when rGP50 was produced in High Five cells. "
01/01/2010 - "We evaluated three diagnostic antigens (recombinant GP50, recombinant T24H, and synthetic Ts18var1) for cysticercosis and found that all three performed well in detecting cysticercosis in humans and pigs in several assay formats. "
01/31/2008 - "We expressed a diagnostic antigen for cysticercosis, GP50, caused by the larval stage of Taenia solium, in both High Five and Sf9 insect cells. "
|4.||Marek Disease (Marek's Disease)
01/01/1995 - "Alignment of the amino acid sequence with those published for HSV gD, equine herpesvirus type 1 (EHV-1) gD, pseudorabies virus (PRV) gp50, Marek's disease virus (MDV) gD, herpesvirus of turkeys (HVT) gD and bovine herpesvirus type 1 (BHV-1) gD showed similarities over the N-terminal region, with the greatest differences occurring in the C-terminal. "
03/01/1984 - "By use of monoclonal antibodies cross-reactive with Marek's disease virus and herpesvirus of turkeys, three glycoproteins (for Marek's disease virus, gp115/110, gp63, and gp50; for herpesvirus of turkeys, gp115, gp62 and gp52) related to virus neutralization were identified. "
|5.||Diffuse Scleroderma (Progressive Systemic Sclerosis)
|6.||Messenger RNA (mRNA)